A phase 1/2 dose escalation study investigated the safety and efficacy of epratuzumab in 56 patients with relapsed or refractory aggressive CD22+ NHL (35 patients with DLBCL) and showed an OR rate of 15% (95% CI, 5% to 32%) in DLBCL patients with a good safety profile [40]. The gene discussed is CD22; the disease is non-Hodgkin lymphoma.